A study published in The Lancet Neurology showed that subcutaneous infusion of ND0612, a levodopa-carbidopa solution, increases on time without troublesome dyskinesia in Parkinson’s disease patients. The study, involving 381 participants, found that compared to oral levodopa-carbidopa, subcutaneous ND0612 provided an additional 1.72 hours of on time without troublesome dyskinesia. Other outcomes, such as daily off time and improvement in Parkinson’s symptoms, also favored subcutaneous ND0612. The authors suggest that ND0612 infusion could be a safe and effective option for managing motor fluctuations in Parkinson’s disease. The study was funded by NeuroDerm, the company developing ND0612.
Source link
Subcutaneous infusion of levodopa-carbidopa beneficial for Parkinson’s disease
